- Email: [email protected]
4935245 Pulverulent, water-dispersible preparation of a sparingly water-soluble pharmaceutical active compound and its preparation
New Patents
4935222
4935245
PROCEDURE FOR ISOLATING AND PURIFYING RADIOACTIVE LIGATED RHENIUM PHARMACEUTICALS AND USE THEREOF AND KIT
PULVERULENT, WATERD I S P E R S I B L E P R E P A R A T I O N O: A SPARINGLY WATER-SOLUBL] PHARMACEUTICAL ACTIVE COMPOUND AND ITS PREPARATION
Edward A Deutsch, Harry Maxon, Karen F Libson, Alan R Ketring assigned to University of Cincinnati A sterile pyrogen free Re196 or Re188 radiopharmaceutical is prepared by reducing radioactive perrhenate in the presence of a bone seeking ligand to form a solution including complexed Re-ligand compound together with impurities such as uncomplexed perrhenate, ReO2 and free ligand. The radiopharmaceutical is obtained by a low pressure purification method. The solution is added to a separation column, preferably an ion exchange column, and a first portion is eluted and discarded. The radiopharmaceutical is collected in a second eluted portion defined as having 25-85% of the activity of the Re on the column, less than 10% unligated perrhenate and less than 1% ReO2. This can be used as is to image and treat metastatic bone leasions. A simple kit is also disclosed.
~35~1 PHARMACEUTICAL PREPARATION FOR TINEA PEDIS Izumi Saitoh, Kaori Ikeda, Shigeru Kido, Yoshio Doi, Shohei Egawa, Hyogo, Japan assigned to Shionogi & Co Ltd A pharmaceutical preparation for the treatment of tinea pedis, containing as basic components about 0.1% to about 2.5% of croconazole hydrochloride and about 1%-15% of an ethyl acrylatemethyl methacrylate copolymer in an aqueous alcohol, and if necessary, about 0.1% to about 2.5% of a thickening agent and/or a plasticizer.
Diete Horn, Reinhard Spengler, Heidelbel Federal Republic Of Germany assigned BASF Aktiengesellschaft An aqueous or pulverulent, water-dispersit pharmaceutical preparation which contains ; emulsifier, a protective colloid and, in mitt disperse form, an edible oil or fat, a sparin~ water-soluble active compound being dissolv in the oil or fat, and a process for its preparatic
4935247 COMPOSITION FOR THE ORAl ADMINISTRATION OF PHARMACEUTICALS Esko Marttila, Ilkka Larma, Kari Vahervu Jaakko Uotila, Perttula, Finland assigned Orion-Yhtyma Oy The invention relates to a new composition f use on a pharmaceutical granule. The compo tion is three-layered, comprising as the i nermost layer a substantially pure fat, as t: middle layer a mixture of fat and polymer, and the outermost layer again a substantially pu fat. The composition according to the inventi~ produces a preparation which is tasteless, esr cially when administered in the form ofa powd or a mixture, even if the phrmaceutical to dosed has a bad taste. Also, the preparati~ keeps well in mixture, and it enables a pharm ceutical to be transported past the stomach f release/absorption at the beginning of the sm~ intestine.
4935404 PHOSPHORUS CONTAINING PEPTIDES, PHARMACEUTICAI COMPOSITIONS AND METHOE OF TREATING COLLAGENOLYTIC CONDITION David J Hunter, Roger E MarkweU, Robert Ward, Essex, United Kingdom assigned Beecham Group p 1 c of Beecham House
4935222
4935245
PROCEDURE FOR ISOLATING AND PURIFYING RADIOACTIVE LIGATED RHENIUM PHARMACEUTICALS AND USE THEREOF AND KIT
PULVERULENT, WATERD I S P E R S I B L E P R E P A R A T I O N O: A SPARINGLY WATER-SOLUBL] PHARMACEUTICAL ACTIVE COMPOUND AND ITS PREPARATION
Edward A Deutsch, Harry Maxon, Karen F Libson, Alan R Ketring assigned to University of Cincinnati A sterile pyrogen free Re196 or Re188 radiopharmaceutical is prepared by reducing radioactive perrhenate in the presence of a bone seeking ligand to form a solution including complexed Re-ligand compound together with impurities such as uncomplexed perrhenate, ReO2 and free ligand. The radiopharmaceutical is obtained by a low pressure purification method. The solution is added to a separation column, preferably an ion exchange column, and a first portion is eluted and discarded. The radiopharmaceutical is collected in a second eluted portion defined as having 25-85% of the activity of the Re on the column, less than 10% unligated perrhenate and less than 1% ReO2. This can be used as is to image and treat metastatic bone leasions. A simple kit is also disclosed.
~35~1 PHARMACEUTICAL PREPARATION FOR TINEA PEDIS Izumi Saitoh, Kaori Ikeda, Shigeru Kido, Yoshio Doi, Shohei Egawa, Hyogo, Japan assigned to Shionogi & Co Ltd A pharmaceutical preparation for the treatment of tinea pedis, containing as basic components about 0.1% to about 2.5% of croconazole hydrochloride and about 1%-15% of an ethyl acrylatemethyl methacrylate copolymer in an aqueous alcohol, and if necessary, about 0.1% to about 2.5% of a thickening agent and/or a plasticizer.
Diete Horn, Reinhard Spengler, Heidelbel Federal Republic Of Germany assigned BASF Aktiengesellschaft An aqueous or pulverulent, water-dispersit pharmaceutical preparation which contains ; emulsifier, a protective colloid and, in mitt disperse form, an edible oil or fat, a sparin~ water-soluble active compound being dissolv in the oil or fat, and a process for its preparatic
4935247 COMPOSITION FOR THE ORAl ADMINISTRATION OF PHARMACEUTICALS Esko Marttila, Ilkka Larma, Kari Vahervu Jaakko Uotila, Perttula, Finland assigned Orion-Yhtyma Oy The invention relates to a new composition f use on a pharmaceutical granule. The compo tion is three-layered, comprising as the i nermost layer a substantially pure fat, as t: middle layer a mixture of fat and polymer, and the outermost layer again a substantially pu fat. The composition according to the inventi~ produces a preparation which is tasteless, esr cially when administered in the form ofa powd or a mixture, even if the phrmaceutical to dosed has a bad taste. Also, the preparati~ keeps well in mixture, and it enables a pharm ceutical to be transported past the stomach f release/absorption at the beginning of the sm~ intestine.
4935404 PHOSPHORUS CONTAINING PEPTIDES, PHARMACEUTICAI COMPOSITIONS AND METHOE OF TREATING COLLAGENOLYTIC CONDITION David J Hunter, Roger E MarkweU, Robert Ward, Essex, United Kingdom assigned Beecham Group p 1 c of Beecham House